Patent ID: 11965036
Assignee: ZYMEWORKS BC INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C  G

Claim 17:
18. A method of treating a subject having a HER2 (human epidermal growth factor receptor 2) expressing (HER2+) tumor comprising administering an effective amount of antigen binding construct to the subject, wherein the antigen binding construct comprises:
a heavy chain 1 (H1), a heavy chain 2 (H2), and a light chain 1 (L1), wherein:
(a) H1 comprises the complementarity determining region (CDR) sequences CDR1, CDR3, and CDR2 set forth in SEQ ID NO: 101, SEQ ID NO: 103, and SEQ ID NO: 105, respectively;
(b) H2 comprises the CDR sequences CDR-L1, CDR-L3, and CDR-L2 set forth in SEQ ID NO:
299, SEQ ID NO: 301, SEQ ID NO: 303, respectively, and the CDR sequences CDR-H1, CDR-H3 and CDR-H2 set forth in SEQ ID NO: 307, SEQ ID NO: 309, and SEQ ID NO: 311, respectively; and
(c) L1 comprises the CDR sequences CDR1, CDR3 and CDR2 set forth in SEQ ID NO: 73, SEQ ID NO: 75, and SEQ ID NO: 77 respectively
wherein the antigen binding construct further comprises a heterodimeric Fc comprising a first Fc polypeptide and a second Fc polypeptide, the first Fc polypeptide comprising a first CH3 sequence and the second Fc polypeptide comprising a second CH3 sequence, wherein the first Fc polypeptide is operably linked to the first antigen-binding polypeptide construct.